Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 14/20 | 1.00 |
| ▸ | F2 | P00734 | 2/20 | 0.96 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.96 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.96 |
| ▸ | TMPRSS6 | Q8IU80 | 2/20 | 0.96 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.96 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3875680 | 0.91 | PRSS1 (0.84) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL12461511 | 0.90 | PRSS1 (0.82) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL14367460 | 0.89 | PRSS1 (0.86) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL1714389 | 0.89 | PRSS1 (0.83) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL5623902 | 0.87 | PRSS1 (0.86) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL17515720 | 0.86 | PRSS1 (0.75) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL3667557 | 0.84 | PRSS1 (0.72) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL12348324 | 0.83 | PRSS1 (0.70) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL14367397 | 0.82 | PRSS1 (0.68) | PRSS1F2PRSS2PRSS3TMPRSS6 | |
| SCHEMBL15145978 | 0.81 | PRSS1 (0.68) | PRSS1F2PRSS2PRSS3TMPRSS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-25 | — | — | US | disclosed |
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2007-01-25 | — | — | US | disclosed |
| EP-1572129-A2 | AMIDINE DERIVATIVES FOR TREATING AMYLOIDOSIS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040147531-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2004-07-29 | — | — | US | disclosed |
| EP-1420773-A1 | AMIDINE DERIVATIVES FOR TREATING AMYLOIDOSIS | Neurochem (International) Limited (CH) | 2004-05-26 | — | — | EP | disclosed |
| US-20040006092-A1 | Amidine derivatives for treating amyloidosis | NEUROCHEM, INC. (CA) | 2004-01-08 | — | — | US | disclosed |
| WO-2003103598-A2 | AMIDINE DERIVATIVES FOR TREATING AMYLOIDOSIS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003017994-A1 | AMIDINE DERIVATIVES FOR TREATING AMYLOIDOSIS | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147531-A1 | Amidine derivatives for treating amyloidosis | APP, IAPP, HTT | PRSS1 1919/4885F2 3667/4885PRSS2 1690/4885 |
| US-20040006092-A1 | Amidine derivatives for treating amyloidosis | APP, IAPP, HTT | PRSS1 1919/4885F2 3667/4885PRSS2 1690/4885 |
| US-20070021483-A1 | Amidine derivatives for treating amyloidosis | APP, IAPP, GRN | PRSS1 2062/4885F2 3712/4885PRSS2 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.